Clinician-level variation in lipid management for secondary prevention of atherosclerotic cardiovascular disease: Opportunities for practice improvement. [PDF]
Am J Prev CardiolNguyen DQ +6 more
europepmc +1 more source
Efficacy and safety of proprotein convertase subtilisin/kexin type 9 inhibitors for adults with familial hypercholesterolemia: A network meta-analysis. [PDF]
Int J Cardiol Cardiovasc Risk PrevDing W, Sun L, Shi Y, Tian L.
europepmc +1 more source
Evolution of siRNA Therapeutics: From Mechanistic Foundations to Clinical Expansion. [PDF]
PharmaceuticsLe QV, Shim G.
europepmc +1 more source
Dyslipidemia in Diabetes: Navigating a Complex Landscape for Improved Cardiovascular Outcomes. [PDF]
Clin Med Insights Endocrinol DiabetesAbdul Wahab R, Wan Mahmood WA.
europepmc +1 more source
Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease: A Network Meta-analysis. [PDF]
Am J Cardiovasc DrugsRaone L +8 more
europepmc +1 more source
Optimal Medical Therapy Targeting Lipids and Inflammation for Secondary Prevention in Patients Undergoing Percutaneous Coronary Intervention. [PDF]
J Clin MedForzano I +17 more
europepmc +1 more source
Related searches:
Cardiovascular disease (CVD) is the leading cause of death worldwide. Hypercholesterolemia has been shown to be one of the most important risk factors for CVD. Statins are currently the standard of care for the management of hypercholesterolemia. However, certain patients on statin therapy fail to achieve the desired low-density lipoprotein cholesterol
C E, Kosmas +3 more
openaire +2 more sources